Page last updated: 2024-11-06

fengabine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Fengabine is a synthetic anticonvulsant medication that acts as a GABAergic drug. It is a structural analog of gabapentin, with a similar mechanism of action. Fengabine binds to the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and inhibiting the release of excitatory neurotransmitters like glutamate. This results in a decrease in neuronal activity and a reduction in seizures. Fengabine has been studied for its potential therapeutic use in the treatment of epilepsy, especially partial seizures. However, it has not been approved for use in the United States or Europe. Fengabine is still under investigation, with studies exploring its efficacy and safety in various patient populations. Research on fengabine focuses on its potential benefits, such as its effectiveness in controlling seizures, its tolerability profile, and its potential to be used in combination with other anticonvulsants. However, further research is needed to determine the long-term efficacy and safety of fengabine.'

Cross-References

ID SourceID
PubMed CID54471
CHEMBL ID2104573
CHEMBL ID3137681
SCHEMBL ID121720
SCHEMBL ID2745394
MeSH IDM0147868

Synonyms (38)

Synonym
2-(n-butylimino-(2-chlorophenyl)methyl)-4-chlorophenol
phenol, 2-((butylimino)(2-chlorophenyl)methyl)-4-chloro-
fengabina [spanish]
2-((butylimino)(2-chlorophenyl)methyl)-4-chlorophenol
sl 79,229-00
sl 79-229
phenol, 2-((butylimino)(2-chlorophenyl)methyl)-4-chloro-, (z)-
fengabine
fengabinum [latin]
(z)-2-(n-butyl-o-chlorobenzimidoyl)-4-chlorophenol
fengabine (usan/inn)
D04149
80018-06-0
AKOS005066244
sl 79.229-00
unii-yqg0nji5a7
fengabine [usan:inn:ban]
yqg0nji5a7 ,
fengabinum
fengabina
sl-79.229
CHEMBL2104573
sl-79229-00
CHEMBL3137681
SCHEMBL121720
fengabine [usan]
fengabine [inn]
SCHEMBL2745394
fengab
Q5443412
sl-79229
(e)-2-((butylimino)(2-chlorophenyl)methyl)-4-chlorophenol
HY-123478
2-[n-butyl-c-(2-chlorophenyl)carbonimidoyl]-4-chlorophenol
2-((butylimino)(2-chlorophenyl)methyl)-4-chloro-phenol
DTXSID401024641
CS-0082767
AKOS040748347

Research Excerpts

Overview

Fengabine (SL 79.229) is a novel benzylidene derivative with clinically proven antidepressant action.

ExcerptReferenceRelevance
"Fengabine is a new GABAmimetic compound active in animal models predictive of antidepressant activity. "( Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics.
Garreau, M; Magni, G; Orofiamma, B; Palminteri, R, 1989
)
3.16
"Fengabine (SL 79.229) is a novel benzylidene derivative with clinically proven antidepressant action. "( Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile.
Bartholini, G; Depoortere, H; Lloyd, KG; Sanger, D; Zivkovic, B, 1987
)
3.16

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic data suggest that fengabine may induce its own metabolism following repeated dosing."( A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers.
Fairweather, DB; Hilton, S; Hindmarch, I; Kerr, JS, 1993
)
0.8

Dosage Studied

ExcerptRelevanceReference
" Dosage ranged from 600 to 2,400 mg/day for fengabine and 50 to 200 mg/day for TCAs."( Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics.
Garreau, M; Magni, G; Orofiamma, B; Palminteri, R, 1989
)
1.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (62.50)18.7374
1990's3 (37.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]